Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as first-line therapy for unresectable RAS/BRAF wild-type metastatic colorectal cancer
2016-004394-40Phase 3Completed
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of panitumumab in metastatic colorectal adenocarcinoma (mCRC), sponsored by Gruppo Oncologico Nord Ovest. Started Sep 2021; status: completed.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2016-004394-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004394-40.